Unique CRF01_AE Gag CTL epitopes associated with lower HIV-viral load and delayed disease progression in a cohort of HIV-infected Thais. 2011

Masahiko Mori, and Busarawan Sriwanthana, and Nuanjun Wichukchinda, and Chetsada Boonthimat, and Naho Tsuchiya, and Toshiyuki Miura, and Panita Pathipvanich, and Koya Ariyoshi, and Pathom Sawanpanyalert
Department of Clinical Medicine, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan.

Cytotoxic T Lymphocytes (CTLs) play a central role in controlling HIV-replication. Although numerous CTL epitopes have been described, most are in subtype B or C infection. Little is known about CTL responses in CRF01_AE infection. Gag CTL responses were investigated in a cohort of 137 treatment-naïve HIV-1 infected Thai patients with high CD4+ T cell counts, using gIFN Enzyme-Linked Immunospot (ELISpot) assays with 15-mer overlapping peptides (OLPs) derived from locally dominant CRF01_AE Gag sequences. 44 OLPs were recognized in 112 (81.8%) individuals. Both the breadth and magnitude of the CTL response, particularly against the p24 region, positively correlated with CD4+ T cell count and inversely correlated with HIV viral load. The breadth of OLP response was also associated with slower progression to antiretroviral therapy initiation. Statistical analysis and single peptide ELISpot assay identified at least 17 significant associations between reactive OLP and HLA in 12 OLP regions; 6 OLP-HLA associations (35.3%) were not compatible with previously reported CTL epitopes, suggesting that these contained new CTL Gag epitopes. A substantial proportion of CTL epitopes in CRF01_AE infection differ from subtype B or C. However, the pattern of protective CTL responses is similar; Gag CTL responses, particularly against p24, control viral replication and slow clinical progression.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013602 T-Lymphocytes, Cytotoxic Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D055815 Young Adult A person between 19 and 24 years of age. Adult, Young,Adults, Young,Young Adults
D058501 Enzyme-Linked Immunospot Assay A method of detection of the number of cells in a sample secreting a specific molecule. With this method, a population of cells are plated over top of the immunosorbent substrate that captures the secreted molecules. ELISPOT,Assay, Enzyme-Linked Immunospot,Assays, Enzyme-Linked Immunospot,Enzyme Linked Immunospot Assay,Enzyme-Linked Immunospot Assays,Immunospot Assay, Enzyme-Linked,Immunospot Assays, Enzyme-Linked

Related Publications

Masahiko Mori, and Busarawan Sriwanthana, and Nuanjun Wichukchinda, and Chetsada Boonthimat, and Naho Tsuchiya, and Toshiyuki Miura, and Panita Pathipvanich, and Koya Ariyoshi, and Pathom Sawanpanyalert
March 2013, AIDS research and human retroviruses,
Masahiko Mori, and Busarawan Sriwanthana, and Nuanjun Wichukchinda, and Chetsada Boonthimat, and Naho Tsuchiya, and Toshiyuki Miura, and Panita Pathipvanich, and Koya Ariyoshi, and Pathom Sawanpanyalert
November 2004, Microbes and infection,
Masahiko Mori, and Busarawan Sriwanthana, and Nuanjun Wichukchinda, and Chetsada Boonthimat, and Naho Tsuchiya, and Toshiyuki Miura, and Panita Pathipvanich, and Koya Ariyoshi, and Pathom Sawanpanyalert
July 2011, AIDS research and human retroviruses,
Masahiko Mori, and Busarawan Sriwanthana, and Nuanjun Wichukchinda, and Chetsada Boonthimat, and Naho Tsuchiya, and Toshiyuki Miura, and Panita Pathipvanich, and Koya Ariyoshi, and Pathom Sawanpanyalert
March 2019, Asian Pacific journal of allergy and immunology,
Masahiko Mori, and Busarawan Sriwanthana, and Nuanjun Wichukchinda, and Chetsada Boonthimat, and Naho Tsuchiya, and Toshiyuki Miura, and Panita Pathipvanich, and Koya Ariyoshi, and Pathom Sawanpanyalert
June 2013, European journal of immunology,
Masahiko Mori, and Busarawan Sriwanthana, and Nuanjun Wichukchinda, and Chetsada Boonthimat, and Naho Tsuchiya, and Toshiyuki Miura, and Panita Pathipvanich, and Koya Ariyoshi, and Pathom Sawanpanyalert
January 2011, PloS one,
Masahiko Mori, and Busarawan Sriwanthana, and Nuanjun Wichukchinda, and Chetsada Boonthimat, and Naho Tsuchiya, and Toshiyuki Miura, and Panita Pathipvanich, and Koya Ariyoshi, and Pathom Sawanpanyalert
May 2012, Cell research,
Masahiko Mori, and Busarawan Sriwanthana, and Nuanjun Wichukchinda, and Chetsada Boonthimat, and Naho Tsuchiya, and Toshiyuki Miura, and Panita Pathipvanich, and Koya Ariyoshi, and Pathom Sawanpanyalert
April 2014, AIDS (London, England),
Masahiko Mori, and Busarawan Sriwanthana, and Nuanjun Wichukchinda, and Chetsada Boonthimat, and Naho Tsuchiya, and Toshiyuki Miura, and Panita Pathipvanich, and Koya Ariyoshi, and Pathom Sawanpanyalert
April 2011, Journal of viral hepatitis,
Masahiko Mori, and Busarawan Sriwanthana, and Nuanjun Wichukchinda, and Chetsada Boonthimat, and Naho Tsuchiya, and Toshiyuki Miura, and Panita Pathipvanich, and Koya Ariyoshi, and Pathom Sawanpanyalert
October 2012, HIV medicine,
Copied contents to your clipboard!